Clinical trials: Schizo-Affective Type of Psychosis
Childhood Schizophrenia, Psychotic Disorder
Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
The purpose of this study is to compare the effectiveness and side effects of the drugs clozapine and olanzapine in children and adolescents with schizophrenia and psychoses.
- Conditions
- Childhood Schizophrenia, Psychotic Disorder, Schizophrenia
- Trial name
- NCT00001656
- Testing
- Olanzapine, Clozapine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Schizoaffective Disorder
Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis
This study will assess the effectiveness of an experimental treatment intervention for adolescents and adults who have experienced their first episode of psychosis during the past two years.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder
- Trial name
- NCT01216891
- Testing
- Multi-element, team-oriented treatment
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
Schizophrenia, Schizo Affective Disorder
Financial Incentives to Improve Medication Adherence
Medication adherence is a challenge in all of medicine and is associated with multiple negative outcomes. Strategies to better measure and enhance adherence to medication are urgent and necessary to minimize unwanted health…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depression
- Trial name
- NCT04191876
- Testing
- Wellth - Financial Incentives
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northwell Health
Schizophrenia
Effectiveness of Targeted Cognitive Training for Neurological Deficits in People With Schizophrenia
This study will determine the effectiveness of reward-intensive, computer-based targeted cognitive training in improving neurocognitive deficits in people with schizophrenia.
- Trial name
- CRIS (NCT00312962)
- Testing
- Targeted cognitive training (TCT), Computer games
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Schizophrenia, Schizoaffective Disorder
A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study was conducted to examine the efficacy and tolerability of ziprasidone intramuscular (IM), and to assess the effect of switching from IM to oral ziprasidone for the treatment of acute exacerbation of schizophrenia and…
- Trial name
- NCT00650429
- Testing
- Ziprasidone
- Where
- 4 sites in Mexico
- Volunteers
- 28 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorder
An Integrated Program for the Treatment of First Episode of Psychosis
The purpose of this study is to determine how services should be provided to reduce symptoms and improve life functioning for adolescents and adults who have been recently diagnosed with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Brief Psychotic Disorder
- Trial name
- RAISE ETP (NCT01321177)
- Testing
- Integrated Treatment, Community Care
- Where
- 33 sites in United States
- Volunteers
- 404 people
- Sponsor
- Northwell Health
Schizophrenia, Schizophreniform Disorder
Optimization of Treatment and Management of Schizophrenia in Europe
The purpose of the study is optimising current treatments in schizophrenia and explore novel therapeutic options for schizophrenia.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- OPTIMISE (NCT01248195)
- Testing
- Amisulpride open label, 6-week amisulpride double blind treatment, 6-week olanzapine double blind treatment
- Where
- 26 sites in Australia, Austria and 14 more
- Volunteers
- 479 people
- Sponsor
- Rene Kahn
Depression, Schizophrenia
Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
This is a research study comparing the safety and efficacy of two active study medications
- Conditions
- Depression, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00034801
- Testing
- olanzapine, ziprasidone
- Where
- 30 sites in United States
- Volunteers
- 378 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizo Affective Disorder
Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)
To characterize the real-life clinical use of AOM in a hospitalized patient population with schizophrenia, schizoaffective disorder or BP1 requiring LAI therapy and evaluate its short-term effectiveness associated with its…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
- Trial name
- INITIATE (NCT04907279)
- Testing
- Aripiprazole Once-Monthly (AOM)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Otsuka Canada Pharmaceutical Inc.
Obesity, Vitamin D Deficiency
Vitamin D Supplementation in Psychiatric Illnesses
Children and adolescents with psychiatric illnesses who are treated with medications called second generation antipsychotic agents (SGA) often gain excessive weight during their treatment with these medications.
- Conditions
- Obesity, Vitamin D Deficiency, Psychosis, Schizophrenia
- Trial name
- VDSS (NCT01004354)
- Testing
- Ergocalciferols
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Massachusetts, Worcester
Psychotic Disorders, Schizophrenia
Effect of Individual Cognitive Stimulation at Home in Adults With Psychotic Disorders
The aim of this study is to test the effect of cognitive stimulation (CS), applied individually and at home, on the overall cognitive functioning, emotional state, functionality, and quality of life (QoL) in adults with psychotic…
- Conditions
- Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT04783285
- Testing
- Individual cognitive stimulation therapy (iCST)
- Where
- Portugal
- Volunteers
- 38 people
- Sponsor
- CEDIARA - Assoc. Solidariedade Social de Ribeira de Fráguas
Severe Mental Illness, Bipolar Disorder
A Mobile App to Support Mood, Daily Routines and Medication Adherence in Adults With Severe Mental Illness
The goal of this clinical trial is to learn whether MoodSync, a mobile application for patients and their family caregivers, improves mood stability, medication adherence, daily functioning and early detection of relapse warning…
- Conditions
- Severe Mental Illness, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- MoodSync (NCT07879131)
- Testing
- MoodSync, Standard care
- Where
- Bahrain
- Volunteers
- 60 people
- Sponsor
- Alexandria University
Schizophrenia, Schizoaffective Disorder
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
- Trial name
- SCRP (NCT00621777)
- Testing
- Varenicline
- Where
- 10 sites in United States
- Volunteers
- 247 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
The primary purpose of this study is to evaluate the overall effect of caregivers receiving a study-provided caregiver psycho-education and skills training program on the number of treatment failures (psychiatric hospitalization…
- Trial name
- FIRST (NCT02600741)
- Testing
- Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate
- Where
- 34 sites in United States
- Volunteers
- 296 people
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia, Treatment-Resistant
An Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Amisulpride in Treating Patients With Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive Symptoms
The objectives of this study are to evaluate the safety and efficacy of Amisulpride as an add-on therapy or alternative monotherapy in treating patients with schizophrenia or schizoaffective disorder who have treatment-resistant…
- Trial name
- AmisulprideTRS (NCT05956600)
- Testing
- Amisulpride 50 MG
- Sponsor
- University of California, Los Angeles
Schizophrenia
Inpatient Evaluation of Adults With Schizophrenia
The purpose of this study is to understand the biologic basis of schizophrenia and to determine which symptoms are related to the illness itself and which are related to medications used to treat the illness.
- Trial name
- NCT00001247
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 648 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Schizoaffective Disorder
Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
Randomized, double-blind clinical trial of tocilizumab vs. placebo as add-on treatment for residual positive, negative, and cognitive symptoms in schizophrenia.
- Trial name
- NCT02034474
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.
The purpose of this study is to document the long-term safety of 25, 50 or 75 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to patients with schizophrenia or schizoaffective…
- Trial name
- NCT00558298
- Testing
- risperidone
- Volunteers
- 811 people
- Sponsor
- Janssen, LP
Schizophrenia, Schizoaffective Disorder
Adjunctive Treatment for Decreasing Symptoms of Schizophrenia
This study will determine the effectiveness of treatment with glycine or d-cycloserine in addition to a normal antipsychotic regimen in improving negative symptoms and cognitive impairments in patients with schizophrenia.
- Trial name
- NCT00222235
- Testing
- d-cycloserine, glycine
- Where
- 5 sites in United States, Israel
- Volunteers
- 240 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Characterizing Response to Antipsychotics in Schizophrenia
The goal of this research project is to develop MRI-based biomarkers to identify patients with schizophrenia who are most likely to benefit from first-line antipsychotic or clozapine treatment.
- Trial name
- NCT06159322
- Testing
- Olanzapine, Clozapine
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- The Royal Ottawa Mental Health Centre